NEWARK, N.J., June 14, 2021 /PRNewswire/ -- Rafael
Holdings, Inc., (NYSE: RFL), a pharmaceutical company focused on
developing novel cancer metabolism therapeutics, today announced
the appointment of three senior biopharmaceutical leaders to its
Board of Directors: Ameet Mallik,
Chief Executive Officer of Rafael Holdings; Shannon Thyme Klinger,
Chief Legal Officer of Moderna, Inc., (NASDAQ GS: MRNA); and
Mark McCamish, M.D., Ph.D.,
President and Chief Executive Officer of IconOVir Bio.
"I am very pleased to have attracted three seasoned and
accomplished executives of Ameet, Shannon and Mark's caliber to the
Rafael Holdings Board," said Howard
Jonas, Chairman of Rafael Holdings. "Each of them
brings deep expertise from their remarkably successful careers to
our Company. Their insights and guidance will prove
tremendously valuable as we advance our pipeline of novel assets
and continue to work toward building and evolving into a fully
integrated commercial company."
"Shannon and Mark are two of the best and brightest leaders
within the industry, and I had the great fortune to work with both
of them at Novartis," said Ameet
Mallik. "They will each bring invaluable experience
and perspectives that will enable us to maximize the potential of
our portfolio of novel therapeutics and progress toward our shared
goal of improving and extending the lives of cancer patients."
Ameet Mallik has over 16 years of
experience at Novartis, where he most recently served as Executive
Vice President and Head, U.S. Oncology responsible for commercial
and medical operations in the United States. Previously, Mr.
Mallik served as the Global Head, Marketing, Value and Access and
as Head, Latin America and
Canada for Novartis
Oncology. Mr. Mallik began his career at Novartis as Head of
Strategic Planning and has held a number of commercial leadership
roles at Novartis and Sandoz, a division of Novartis. At Sandoz,
Mr. Mallik was Head of Biopharmaceuticals & Oncology
Injectables.
Shannon Thyme Klinger serves as Chief Legal Officer of Moderna.
Ms. Klinger also serves on Moderna's Executive Committee and as
Corporate Secretary. Before joining Moderna, Ms. Klinger served as
Chief Legal Officer and a member of the Executive Committee at
Novartis from 2018 to 2021. During Ms. Klinger's ten-year tenure at
Novartis, she held other roles of increasing responsibility,
including as Novartis' Chief Ethics, Risk & Compliance Officer
and as the as Global Head Legal and General Counsel for Sandoz, a
Novartis division. Shannon brings important global pharmaceutical
experience across a wide range of strategically-important areas
including legal, compliance, IP, business development, licensing,
mergers and acquisitions, public/government affairs,
communications, risk management, quality, and regulatory
affairs.
"I am excited to be working again with Ameet and look forward to
joining Howard Jonas and my
colleagues on the board in partnering with the management team as
the company continues its development of devimistat and focuses on
further building out a pipeline focused on new approaches to
fighting cancer," Ms. Klinger stated.
Mark McCamish, MD, Ph.D., is
President and Chief Executive Officer at IconOVir Bio, and
previously served as the President and Chief Executive Officer of
Forty Seven, Inc., where he led the company through critical phases
of clinical development and its acquisition by Gilead (Nasdaq:
GILD). Dr. McCamish is an international expert in biologic
and biosimilars development and manufacturing and held senior
executive roles at leading global pharmaceutical companies,
including Abbott, Amgen, and Novartis/Sandoz. He led pioneering
efforts in filing and launching biosimilars worldwide. Dr.
McCamish is passionate about mentoring and developing people while
focusing on meeting patient needs through efficient, commercially
viable efforts.
"It is a true pleasure to be united again with Ameet to address
patient's needs through a unique metabolic approach to fighting
cancer," said Dr. McCamish. "I am impressed with how
Howard Jonas and his team have
advanced devimistat into the clinic with perseverance and urgency
and I believe Ameet is the perfect leader to move the company
forward to maximize patient benefit."
About Rafael Holdings, Inc.:
Rafael Holdings is
focused on development of novel cancer therapies. The company
is a significant investor in two clinical stage oncology companies,
Rafael Pharmaceuticals, Inc. and LipoMedix Pharmaceuticals
Ltd. Through its wholly owned Barer Institute subsidiary, the
company is developing a pipeline of compounds focused on the
regulation of cancer metabolism. For more information, visit
www.rafaelholdings.com.
About Rafael Pharmaceuticals, Inc.:
Rafael
Pharmaceuticals is a clinical-stage oncology company focused on
selectively targeting cancer metabolic pathways while
simultaneously harnessing the immune system to attack hard-to-treat
cancers. The Company's lead drug, CPI-613 (devimistat), is being
evaluated in multiple clinical studies including two Phase 3
registrational clinical trials for metastatic pancreatic cancer and
r/r acute myeloid leukemia. Multiple Phase 1/2 clinical trials are
ongoing or planned in Biliary, r/r Burkitt, r/r Clear Cell Sarcoma,
r/r T-cell lymphoma, r/r MDS, and Colorectal cancer.
The Company is continuing advance its internal cancer metabolism
research programs and expects its Dual-SHMT Inhibitor to enter
Phase 1 in late 2022. Raphael Pharmaceuticals' investors include
Rafael Holdings, Inc. (NYSE: RFL). For more information, please
visit https://rafaelpharma.com/.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/rafael-holdings-appoints-three-highly-experienced-biopharmaceutical-leaders-to-its-board-of-directors-301311908.html
SOURCE Rafael Holdings, Inc.